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 Leishmaniasis is an endemic disease caused by the protozoan parasite 
Leishmania.  Current treatments for the parasite are limited by cost, availability, and 
drug resistance as the worldwide occurrence of leishmaniasis continues to be more 
prevalent.  Sulfonamides are a class of compounds with medicinal properties that have 
been used to treat bacterial and parasitic diseases via various pathways.  In this study, 
newly synthesized, unique structural analogs of sulfonamide compounds were 
assessed for their impact on Leishmania cell viability and potential pathways for 
inhibition were evaluated.  Leishmania tarentolae (ATCC Strain 30143) axenic 
promastigote cells were grown in BHI medium and treated with varying concentrations 
of the unique sulfonamide compounds.  Light microscopy and viability tests were used 
to assess the cells with and without treatment.  Recombinant Leishmania major 
dihydrofolate reductase-thymidylate synthase (DHFR-TS) bifunctional enzyme was 
expressed in E. coli, extracted, and purified.  DNA sequencing at University of Illinois, 
Urbana-Champaign (UIUC) confirmed the gene was expressed correctly, but the 
recombinant protein did not exhibit catalytic activity.  Future work should include 
evaluation of the inhibitory effects of the sulfonamides on the recombinant DHFR-TS.  
 
The conclusions of this work will help determine potential applications for tested 
sulfonamides improving future medicinal therapies for this disease.   
 
KEYWORDS: Leishmania, Leishmaniasis, Sulfonamide, Potential Treatment, 
Promastigote 
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CHAPTER I 
INTRODUCTION 
LEISHMANIASIS AND LEISHMANIA 
 Leishmaniasis is a disease caused by protozoan parasites of the genus 
Leishmania. Leishmaniasis is transmitted by sandflies and is often found in areas of 
Africa, Central and South America, the Mediterranean regions, Central and East Asia, 
and Southeastern Europe  The disease is endemic in over eighty countries worldwide 
and is considered a dangerous public health concern with an incidence of 1.3 - 2 million 
affected each year with approximately 310 million at risk of infection. 1  The disease can 
present in three main ways: cutaneous, mucocutaneous, or visceral leishmaniasis. 2 
 Cutaneous leishmaniasis, the most common form, causes painful sores that may 
start as papules or nodules and end as ulcers that may develop within a few weeks or 
months after parasite transmission to the host.  Species of Leishmania known to cause 
cutaneous leishmaniasis include Leishmania tropica, L. major, L. aethiopica, L. 
infantum, and L. donovani in the Old World (Eastern Hemisphere) and include the L. 
mexicana species and the subgenus Viannia species in the New World (Americas). 3  
 Mucocutaneous, or mucosal, leishmaniasis is a consequence of the Viannia 
subgenus of Leishmania infecting the mucous membranes of the nose, mouth, or throat, 
typically after years of cutaneous infection.  This type of leishmaniasis can cause severe 
physical damage to the infected areas.3 
 Visceral leishmaniasis is the most life threatening form of the disease, as it 
affects internal organs such as the spleen, liver, and bone marrow.  Hosts typically 
develop the disease months to years after the initial infection, which can cause fever, 
2 

swelling of the spleen and liver, and reduced red blood cell, white blood cell, and 
platelet counts. 4  Visceral leishmaniasis is usually caused by the L. donovani,  L. 
infantum or L. chagasi species. 3 
 Studies have shown that Leishmania tarentolae, a species isolated from the 
gecko Tarentolae annularis, is a suitable model for in vitro screening of anti-leishmanial 
compounds.  Because this form of Leishmania is not infectious to humans, the axenic 
form of the parasite is considered suitable for preliminary potential anti-leishmanial 
compound studies. 5   
 Leishmania are digenic and can exist as two cell stages: amastigotes and 
promastigotes.  As can be seen in Figure 1, 3 the promastigote stage of Leishmania is 
transferred to an alternative host upon feeding by an infected sandfly. 6  A macrophage 
or other phagocytic cells in the immune system phagocytize the cells.  Once in the 
phagocytic cell, the Leishmania transform to the amastigote stage, which is 
characterized by a more spherical shape and loss of flagellum.  Amastigotes replicate in 
the phagocytic cell until its rupture and the subsequent release of amastigotes thus can 
lead to infection of other phagocytic cells.  The amastigote stage of the Leishmania has 
several characteristics different from the promastigote stage, including changes in gene 
expression leading to enzymatic changes that allow the cells to survive in the acidic 
environment of a phagocytic cell. 7   
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Figure 1. Life cycle of Leishmania. Leishmania present as different cell stages within 
their lifecycle, with different cell morphology and genes expressed (modified from 
Centers for Disease Control and Prevention3).     
 
 
 
 
 The diversity in presentation of leishmaniasis owing to the many different species 
of the parasite make it a difficult treatment target.  In addition, the life cycle of the 
parasite leads to changes in gene and enzyme expression in the different hosts, 
presenting additional complexity in identifying and designing small molecules for 
specific drug targets.  With the disease affecting nearly 2 million people annually, 
identifying new therapeutics has become more pertinent in preventing spread and 
improving quality of life for those affected. 
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CURRENT TREATMENTS FOR LEISHMANIASIS 
 Treatments exist today for the three types of leishmaniasis; 2 however, due to the 
infections primarily occurring in developing countries with weak infrastructure and 
impoverished economies, access to these treatments is costly and complicated.  
Advancement of known and new treatments is largely ignored and the World Health 
Organization (WHO) has considered leishmaniasis a “neglected” disease. 1  Common 
treatments for leishmaniasis generate increasing concerns over variable responses in 
different species of the infective parasite, as well as failure in treatment due to 
resistance from overuse.   
 Pentavalent antimonial (SbV) drugs are typically the first line of defense for all 
types of leishmaniasis infections, though studies have shown SbV drugs to have three- 
to fivefold greater sensitivity in L. donovani and L. brasilensis species compared to L. 
major, L. tropica, and L. mexicana species. 8  However, many scientists believe that 
because of widespread overuse, the acquired resistance to the treatment has increased 
and some species of the parasite have become refractory to the treatment. 9 
 Amphotericin B, a polyene antibiotic, has been used in areas with SbV drug 
resistance with some success.  However, side effects are reported to be a concern. 10  
Clinical resistance to amphotericin B is currently rare, but with the increasing use of the 
treatment in place of antimonial drugs, it is expected that resistance could become an 
issue. 9  Resistant clones of L. donovani promastigotes have been identified in cell 
cultures and have been seen to express mutations with changes in the sterol profile of 
their plasma membrane. 11 
5 
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 The first oral agent approved for treatment of leishmaniasis is miltefosine, with 
cure rates of 94% for visceral leishmaniasis 12; however, the drug maintains 
subtherapeutic levels due to its slow clearance in the host that may lead to greater 
opportunity for drug resistance. 13  Studies have shown variation in sensitivity of 
amastigote and promastigote forms of different species of Leishmania to miltefosine, 
with L. donovani being the most sensitive and L. major being the least. 14 
 Other therapies are also available, but the opportunity for resistance in different 
species of the parasite as a function of use and application is high. 9  In 2010, the World 
Health Organization identified high cost of medicines, treatment availability, lack of 
updated protocols for application, and non-continuous supply of the most effective 
treatments to be the largest hurdles for treatment of the disease in the most highly 
impacted regions of the world. 15  Availability of treatments with greater ease of use, 
lower treatment rates, and less sensitivity to resistance would be of great benefit 
globally.   
 
SULFONAMIDES AND THEIR INHIBITORY EFFECTS 
 One possible treatment option for leishmanisis is the development of unique 
sulfonamides that target parasite cell function and inhibit cell viability and proliferation 
while causing minimal negative side effects for the host.  Sulfonamide drugs are 
characterized by the presence of a –S(=O)2-NH2 functional group in the compound.  
Sulfonamides became popular antibacterial agents in the 1940s, though the first 
sulfonamide drug, Prontosil (Figure 2) was first patented in 1932. 16  The drug was 
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synthesized by Josef Klarer and Fritz Mietzsch and found effective against bacterial 
infections in mice by Gerhard Domagk in 1932, and in 1939 Domagk was awarded the 
Nobel Prize in Medicine for his work with the first medicine that could treat a range of 
bacterial infections in humans. 17  Sulfonamides, or sulfa drugs, are commonly used as 
chemotherapeutic and preventative medicines for various diseases, with over 30 such 
drugs being in clinical use as of 2014. 18  Sulfa drugs have been used as 
antihypertensive, 19 antibacteria,l 20 antiprotozoal, 21 antifungal, 22 and anti-inflammatory 
agents. 18  Sulfonamide derivatives have also been used to treat urinary, intestinal, and 
ophthalmic infections, burns, ulcerative colitis, 23 rheumatoid arthritis, 24 and more 
recently, cancer, 25 Alzheimer’s disease, 26 and HIV. 27 
 
 

Figure 2. Chemical structure of Prontosil. 16 
 
 
 Potential side effects of sulfa drugs include skin rash, itching, headache, 
dizziness, diarrhea, tiredness, nausea or vomiting, pale skin, joint pain, and sensitivity to 
light, and allergies to sulfonamides and other sulfa drugs are common. 28  The side 
effects of anti-leishmanial SbV drugs often include nausea and vomiting, joint pain, 
hepatitis, pancreatitis and cardiac dysrhythmias and require frequent monitoring for 
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toxicity. 29  Clinical studies with amphotericin B have shown infusion reactions and renal 
impairment while miltefosine, in the active oral form, has some reproductive toxicity as 
well as gastrointestinal side effects, which can cause nausea and vomiting. 29  Severity 
of side effects are dependent on treatment concentrations and accumulation in patients.  
Though sulfonamides have been seen to form renal crystals, this can be managed by 
monitoring treatment concentrations and could potentially be reduced by improving 
water solubility. 30   
 Studies have identified the primary pathway of sulfonamide inhibition as 
competitive inhibitors of the enzymes dihydropteroate synthase (EC 2.5.1.15) and 
dihydrofolate reductase (EC 1.5.1.3; DHFR), enzymes involved in folate metabolism. 31  
Folate synthesis and the products of the folate pathway are important in the synthesis of 
purines and DNA.  This pathway of inhibition is also a primary method of treatment of 
cancers using sulfonamide drugs, 32 as it prevents the replication of DNA and cell 
proliferation.  Other modes of inhibition induce disruption of microtubule activity, thereby 
decreasing cell division. 33  Studies have also shown that the inhibition of DHFR can 
allow for an accumulation of NADPH, which would have an inhibitory effect on glucose-
6-phosphate dehydrogenase in the oxidative phase of the pentose phosphate   
pathway. 34  The pentose phosphate pathway has two primary functions: regeneration of 
reduced form of nicotinamide adenine dinucleotide phosphate (NADPH) for use in 
multiple pathways and generation of pentoses, which are necessary for nucleic acid 
synthesis. 35 
 Sulfonamides are typically prepared by reacting a sulfonyl chloride compound 
containing the desired side chain with ammonia or an amine containing the second 
8 
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desired side chain, making the process fairly simple and low cost. 18  Due to the stability 
of these compounds, if stored properly, they can have a shelf life of approximately two 
years. 36  Sulfa drugs can be applied orally, topically, or intravenously, 37 allowing them to 
be good treatments for all three types of leishmaniasis.   
 
FOLIC ACID METABOLIC PATHWAYS 
 As shown in Figure 3, the various intermediary metabolites of folate have a 
variety of roles, as cofactors, in a variety of pathways, especially in one-carbon 
transfers. 38  Thus, amino acid metabolism, choline derivatives (such as 
phosphatidylcholine formation from phosphatidylethanolamine), as well as nucleic acid 
metabolism can be affected as folic acid metabolism is affected. 39 
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Figure 3. The folate metabolic pathway. 39 
  
 
 
 
 Sulfonamides have been used to treat bacteria and Leishmania species perhaps 
by mainly inhibiting the enzymes dihydropteroate synthetase (DPS) and dihydrofolate 
reductase (DHFR). 7  These enzymes are essential in the production and metabolism of 
folate, affecting the synthesis of DNA.  DHFR, specifically, allows for the reduction of 
7,8-dihydrofolate (H2F) to 5,6,7,8-tetrahydrofolate (H4F) while oxidizing the NADPH to 
NADP+ (Figure 4). 40   
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Figure 4. Reaction catalyzed by DHFR. Dihydrofolic acid (H2F) is reduced to 
tetrahydrofolic acid (H4F) with the oxidation of NADPH to NADP+. 40 
 
 
 
 The proposed mechanism for the DHFR enzyme, from Mycobacterium 
tuberculosis, is shown in Figure 5. 41  The primary coordinating amino acid of the 
dihydrofolate binding pocket is an aspartate or glutamate, dependent on species, as the 
carboxyl group of the amino acid is important in hydrogen bonding to the pterin ring of 
the dihydrofolate.  Water is also necessary to ensure a proton transfer occurs along with 
the hydride transfer from NADPH, allowing for the final product of tetrahydrofolate (H4F).   
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Figure 5. Proposed catalytic mechanism by DHFR from Mycobacterium tuberculosis. 41 
 
 
 
 DHFR activity is the major endogenous source for H4F, and is important in 
maintaining the cellular pools of H4F and its derivatives for the synthesis of purines and 
thymidylate among other highly important products.  Without DHFR, cells are unable to 
grow and proliferate without addition of exogenous H4F. 40  Because of this, DHFR is a 
primary target for treatment against rapidly growing cells, such as bacteria, parasites, 
and even cancers.   
 It is important to note, however, that Leishmania have a more complex pathway 
of folate metabolism than bacteria.  Leishmania contain a bifunctional polypeptide form 
12 
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of DHFR that also encodes thymidylate synthase (EC 2.1.1.45) (TS), meaning the 
enzyme, DHFR-TS, is reversible in the presence of N5, N10 – methylene tetrahydrofolate 
(CH2=H4F) and deoxyuridine monophosphate (dUMP).  Although the TS enzyme is 
present ubiquitously among cells, it is typically only found in the bifunctional form in 
protozoa and plants. 42   In addition, a second enzyme, pteridine reductase 1 (EC 
1.5.1.33) (PTR1), has been identified to reduce folates and unconjugated pteridines in 
the folate pathway, as seen in Figure 6. 43  PTR1 can act as a metabolic bypass of 
DHFR inhibition drugs solely targeting tetrahydrofolate production by the bifunctional 
DHFR-TS enzyme and halting single carbon metabolic pathways. 44   
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Figure 6. The folic acid metabolic pathway for Leishmania. The proposed metabolic 
pathway for folate and biopterin in Leishmania, showing PTR1 can catalyze both the 
reduction of folate and dihydrofolate (H2F) to tetrahydrofolate (H4F), which are essential 
steps in the synthesis of DNA. 43 
 
 
 PTR1 plays an important role in the salvage and oxidation of pterins. 44  Studies 
have shown that DHFR-TS has no role in the reduction of pterines, but PTR1 can have 
significant activity with folates, increasing the opportunity for DHFR drug target 
resistance in Leishmania. 44  Though the role of biopterin in trypanosomatids is not well 
established, PTR1 and quinoid dihydropteridine reductase (qDPR) have been identified 
as important for recycling quinonoid dihydrobiopterin (Figure 7). 44  This recycling may 
also have an important role in the biosynthesis of tyrosine for these parasites (Figure 7).  
Studies have also shown that mutants lacking PTR1 are unable to survive, even in the 
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presence of folate or dihydrofolate 45 and, therefore, play an important role in 
Leishmania growth and viability.  Because of this additional enzyme complexity, 
determining the pathways of inhibition of specific treatments is important in determining 
the efficacy of a drug and likelihood for species resistance.    
 
 
Figure 7. Metabolic pathway of biopterin in L. major. 46   
 
 
 
 In this thesis, newly synthesized, unique sulfonamide compounds were assessed 
for their impact on Leishmania tarentolae cell viability and potential pathways of 
inhibition were investigated.  Due to the known inhibitory effects of sulfonamides on 
DHFR, the folate pathway was a focus of interest.  Axenic promastigotes (ATCC Strain 
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30143) were grown in brain heart infusion (BHI) medium and treated with varying 
concentrations of the synthesized sulfonamides.  Light microscopy and viability tests 
were used to assess the cells with and without treatment.  The folic acid pathway was 
probed by adding folic acid to the cells and evaluating the effects with and without 
treatment.  Recombinant DHFR-TS from L. major was expressed in E. coli, extracted, 
and purified.  Enzyme activity was evaluated by measuring the oxidation of NADPH to 
NADP+ using change in absorbance at 340 nm. 47  However, catalytic activity was not 
exhibited by the enzyme and additional work is needed to evaluate the effects of the 
unique inhibitory sulfonamides on DHFR-TS from Leishmania.  Understanding the form 
and inhibitory function of these sulfonamide compounds would be helpful in developing 
treatments for Leishmania that may overcome the many complexities of their infective 
capability.   
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CHAPTER II 
MATERIALS AND METHODOLOGY 
PROMASTIGOTES 
Leishmania tarentolae promastigotes (ATCC Strain 30143, American Type 
Culture Collection) were grown in sterile conditions in brain heart infusion (BHI) medium 
supplemented with penicillin and streptomycin (100 units and 0.1 mg per mL 
respectively) and hemin (10 µM) in flasks (Falcon, polystyrene) following the method of 
Morgenthaler et al. 48  Promastigote forms of the Leishmania cells were transferred 
during the log phase of the growth curve to maintain cell cultures.  Work with 
promastigotes was performed in a sterile hood to prevent contamination.  
 
MTT ASSAY 
The 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT) assay 
was used to evaluate promastigote viability at different points in the growth curve and 
after treatments.  The MTT assay is a colorimetric assay which assesses cell viability 
based on the activity of oxidoreductase enzymes. 49  These enzymes reduce the yellow 
tetrazolium reagent to an insoluble, purple formazan.  One hundred microliters of cells 
were transferred to wells of a 96 well plate (Fisher, polypropylene), 4 replicates to allow 
for calculation of mean and standard deviation, then 10 µL of MTT reagent (Sigma, 5 
mg per 1 mL water) was added to each well with gentle mixing.  Cells and reagent were 
allowed to incubate for 1 hour before the addition of the stopping agent which consists 
of 10% Triton X-100 (v/v), 225 mL isopropanol, and 2 mL 0.14 M hydrochloric acid.  A 
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96 well plate reader spectrophotometer (BIO RAD, iMark Microplate Reader) was then 
used to obtain absorbance data at 595 nm.  BHI medium, without cells, treated with 
dimethyl sulfoxide (DMSO) or the same concentration of sulfonamide in DMSO being 
tested were used as blanks as appropriate.  Corrected absorbance at 595 nm is then 
assumed to correlate with the amount of viable cells present.   
 
MICROSCOPY 
Light microscopy (JENCO, Model CP-2A1) was used to qualitatively assess cells 
for shape, clumping, and cell motility.  Cells were evaluated in the flasks, without 
fixation, since this is an inverted microscope.  Pictures and videos were obtained with a 
Kodak EasyShare C743 camera. 
 
SULFONAMIDE SYNTHESIS AND CHARACTERIZATION 
Starting materials were obtained from commercial sources and used as received.  
Dr. Hamaker synthesized N-(2’-methylthiophenyl)-1-napthalene sulfonamide 
(Compound A), N-(2’-methoxyphenyl)-1-napthalene sulfonamide (Compound B), and N-
(2’-methylphenyl)-1-napthalene sulfonamide (Compound C) by reaction of 1-
naphthalene sulfonyl chloride with the appropriate aniline in pyridine.  A 500 MHz NMR 
was used to acquire 1H spectra for samples in DMSO-d6.  The generic reaction is 
shown in Figure 8. 50   
18 
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Figure 8.  Generic reaction to synthesize sulfonamides.  Sulfonamides A, B, and C 
were synthesized when 1-napthalene sulfonyl chloride was mixed with the appropriate 
aniline in pyridine. 
 
 
 
To synthesize N-(2’-methylphenyl)-(4-carboxyl)-1-napthalene sulfonamide 
(Compound D), 30 mL of aqueous 1 M sodium carbonate containing 2.200 g (9.710 
mmol) of 1-napthalenesulfonyl chloride and 1.528 g (10.11 mmol) 3-methyl-4-
aminobenzoic acid was prepared in a 250 mL Erlenmeyer flask.  The solution was 
allowed to stir for 24 hours and then acidified with 6 M hydrochloric acid.  The 
precipitate was filtered and washed with water.  The precipitate that formed was 
collected by vacuum filtration, washed with water, and air dried overnight to yield 1.765 
g (47.33%) of Compound D as a light pink solid.  1H NMR (500 MHz, (CD3)2SO): 12.73 
(br s, 1H, COOH); 10.16 (s, 1H, NH); 8.73 (d, 1H, aromatic); 8.23 (d, 1H, aromatic); 
8.09 (m, 2H, aromatic); 7.69 (m, 2H, aromatic); 7.59 (m, 3H, aromatic); 7.20 (d, 1H, 
aromatic); 1.95 (s, 3H, -CH3) (Appendix A). 50 
To synthesize N-(4-carboxyl)-1-naphthalene sulfonamide (Compound E), 25 mL 
of aqueous 1 M sodium carbonate in a 125 mL Erlenmeyer flask was charged with 
1.371g (10.00 mmol) of anthranilic acid and 2.269 g (10.01 mmol)                                 
1-naphthalenesulfonyl chloride. The solution was stirred for 20 hours and acidified with 
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6 M hydrochloric acid. The precipitate that formed was collected by vacuum filtration, 
washed with water, and air dried overnight to yield 2.588 g (74.01%) of Compound E as 
a white solid. 1H NMR (500 MHz, (CD3)2SO): 13.90 (br s, 1H, COOH); 8.62 (d, 1H, 
aromatic); 8.31 (d, 1H, aromatic); 8.19 (d, 1H, aromatic); 8.04 (d, 1H, aromatic); 7.79 (d, 
1H, aromatic); 7.69 (t, 1H, aromatic); 7.63 (m, 2H, aromatic); 7.34 (m, 2H, aromatic); 
6.88 (t, 1H, aromatic) (Appendix B). 50   
 
EVALUATION OF SULFONAMIDE TREATMENT OF PROMASTIGOTES 
The sulfonamides were dissolved in DMSO and added to promastigotes grown in 
BHI medium.  A large volume (60 mL) of cells were grown in a single flask (Falcon, 75 
cm2 polystyrene) and transferred to smaller flasks, 5 mL (Falcon, 12.5 cm2 polystyrene) 
or 10 mL (Falcon, 25 cm2 polystyrene) for treatment.  This was done in an effort to 
reduce variation in number and age of cells in each test flask.  Promastigotes were 
treated with varying concentrations of the sulfonamides (between 10 µM and 100 µM) 
dissolved in DMSO, ensuring cells were exposed to no more than 1% (v/v) DMSO, at 
different points in the growth curve for the cells (Figure 9).  Untreated cells and cells 
treated only with the same final volume DMSO were used as controls for these studies.  
Blank samples were used to calculate the corrected average absorbance of the cellular 
samples by subtracting the absorbance values of the blanks from the cellular values.  
MTT assays were used to quantitatively evaluate cell viability, while light microscopy 
was used to qualitatively assess cells for shape, clumping and cell motility.  Each 
experiment was performed in four wells in at least three experiments to confirm 
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repeatability and a statistical Students t-test was used to determine statistical 
significance for the results (p < 0.05 was considered significantly different).  Cultures 
determined to be severely inhibited were transferred to fresh medium to determine if 
they were in early or late senescence phase and could recover.  Those without recovery 
(measurable MTT response) over 3 days were considered fully inhibited (dead). 
 
 
Figure 9. Typical growth curve for Leishmania tarentolae promastigotes.  The graph 
shows the typical growth curve and phases for Leishmania tarentolae promastigotes, 
where absorbance at 595 nm is representative of cell viability as a function of day in 
culture.  Each point is a mean ± standard deviation of n = 4. 
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 Cells shape, motility, and clumping were assessed with inverted light microscopy 
daily.  The results were documented subjectively and photography or video were used 
as necessary for further documentation.   
 
POTENTIAL PATHWAY OF INHIBITION INVESTIGATION 
Potential pathway of inhibition in the presence of those sulfonamides with effects 
on cell viability was evaluated by adding folate to the medium in concert with the 
sulfonamide addition.  If the pathway of inhibition is related to the folic acid metabolic 
pathway, the cells should have improved viability when folate is added in the presence 
of the sulfonamide.  If folate does not protect the cells there is likely a different 
pathway(s) of inhibition.   
 Cells were grown in the same manner as described above.  Promastigotes were 
treated with the most effective concentration of the sulfonamides shown to have a 
negative effect on cell viability (100 µM) and the same concentration of folate.  Both 
were dissolved in the same vial of DMSO, and cells were treated with the combination, 
ensuring cells were exposed to no more than 1% (v/v) DMSO, in the log phase of cell 
growth.  Untreated cells, cells treated only with 1% volume DMSO, cells treated with 
100 µM folate, and cells treated with 100 µM sulfonamide were used as variables for 
these studies.  MTT assays were used to quantitatively evaluate cell viability, while light 
microscopy (JENCO, Model CP-2A1) was used to qualitatively assess cells for shape, 
clumping and cell motility.  Each experiment was performed at least three times to 
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confirm repeatability and a statistical Students t-test was used to determine statistical 
significance for the results (p < 0.05 was considered significantly different).  Cultures 
determined to be severely inhibited were transferred to fresh medium to determine if 
they were in early or late senescence phase and could recover.  Those without recovery 
(measurable MTT response) over 3 days were considered fully inhibited (dead). 
 
DNA AMPLIFICATION BY PCR 
 To evaluate the enzyme DHFR-TS from L. major, the gene encoding DHFR-TS 
was cloned using polymerase chain reaction (PCR) DNA amplification and the encoded 
protein was expressed in E. coli cells.  Leishmania major was chosen for this work, as it 
is one of the human infective forms of the parasite, so studies related to therapeutic 
inhibition of DHFR-TS would be applicable to a medically relevant form of the parasite.  
Also, the genome for this species has been sequenced (Genbank ID: M12734). 51  
Standard methods used were adapted from Sambrook and Russell, Molecular Cloning – 
A Laboratory Manual. 52   
 Single-stranded DNA primers (Sigma) complementary to the 5’- and 3’- ends of 
the gene were designed to amplify the gene encoding L. major DHFR-TS (Genbank ID: 
M12734).  When the primers are present in solution with genomic DNA from L. major, 
the primers hydrogen bond with the complementary DNA of the gene of interest.  PCR 
(MJ Research, PTC-200 Peltier Thermal Cycler) was used to amplify the gene of 
interest between the primers.  After incubation at 94°C for 5 minutes, the PCR 
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amplification, using the PCR Master Mix (Promega), involved the following program:  
94°C for 15 seconds, 50°C for 30 seconds, and 72°C for 1 minute; 30 complete cycles 
were performed.  At 94°C the double stranded DNA template, from L. major, denatures 
to form single strands of DNA to which the primers anneal at 50°C.  This is then heated 
to 72°C, where the OneTaq DNA polymerase (New England BioLabs, 2x concentration) 
elongates the primers from the 5’-3’ direction.  The volumes of materials used in the 
PCR amplification are shown in Table 1.  Deoxy ribonucleotide (present in the PCR 
MasterMix, Promega, 2x concentration) addition occurs on both strands, and after 30 
cycles 230 DNA strands, in theory, were synthesized.   
 
 
Table 1.  Materials and volumes used for PCR amplification of the DHFR-TS gene.  
 
 
 
The primers were designed to include start and stop codons for the gene, the 
appropriate nucleotide sequence to code for restriction enzyme target regions for 
BamHI and HindIII, and 17 nucleotides of the 5’- sequence of the DHFR-TS gene, and 
22 nucleotides of the 3’- sequence of the DHFR-TS gene, as seen in Figure 10.  The 
primers were ordered from Sigma-Aldrich.   
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Figure 10. Primer sequences designed for PCR amplification of the L. major DHFR-TS 
gene.  The BamHI restriction enzyme sequence (GGATCC) is underlined in the 5’- 
strand of the primer, and the HindIII restriction enzyme sequence (AAGCTT) is 
underlined in the 3’- strand.  The start codon, ATG, and stop codon, CTA, are shown in 
bold, and the nucleotides of the gene are in the boxed region.   
 
Agarose gel (1.4% (w/v)) electrophoresis was used to analyze the amplified 
DNA.  The gel was prepared by adding 1.4 g agarose (ISC BioExpress, GenePure LE 
Quick Dissolve Agarose) to 100 mL 0.5x TBE Buffer (44.5 mM Tris base, 44.5 mM boric 
acid, and 1 mM EDTA, purchased from Fisher) and microwaving until dissolved.  After 
cooling to approximately 50°C, 3 µL SYBR safe (Invitrogen) was added as an 
intercalating fluorescent dye for visualization of DNA under UV light.  The mixture was 
poured into an agarose gel mold.   
The PCR material was purified using a PCR purification kit (PureLinkTM Quick 
PCR Purification Kit, InvitrogenTM).  The PCR samples and pET-45b plasmid were 
digested with BamHI (New England BioLabs, 20,000 U/mL) and HindIII (New England 
BioLabs, 20,000 U/mL ) enzymes for 4 hours using volumes shown in Table 2.  The 
pET-45b plasmid encodes a six histidine tag (His-tag) within the reading frame for the 
inserted gene; therefore, the expressed protein should contain a His-tag that can be 
used for protein purification on a cobalt or nickel resin column.  The plasmid also 
encodes a gene for ampicillin resistance.   
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Table 2.  Respective volumes for DNA digestion of PCR products and plasmid. 
 
 
 
 To 15 µL of sample from the restriction enzyme digestion, 5 µL Blue/Orange 
Loading Dye (Promega, 6x) was added.  A standard 1 kilo-base pair (Kb) ladder 
(Promega) was used as a molecular weight standard for comparison (Figure 11).  Five 
µL of the standard and 15 µL of sample were loaded onto separate lanes of the gel.  
Then 150 voltage was applied for approximately 45 minutes.  Results were visualized 
using a fluorescent gel imaging system (Kodak, Gel Logic 200 Imaging System) and 
imaging software (Kodak ID 3.6).   
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Figure 11. Promega 1 Kb Ladder standard in 0.7% agarose gel. 53 
 
RECOMBINANT GENE LIGATION 
 To improve the likelihood of a successful ligation, DNA with the expected number 
of base pairs (approximately 1500 base pairs) for the DHFR-TS gene and pET-45b 
plasmid were cut directly from the gel and purified using a DNA purification kit (DNA 
Purification System, Promega).  Ligation of the amplified DNA and the pET-45b plasmid 
was performed with different volumes of plasmid and PCR material, as shown in Table 
3.  The materials were incubated at 15°C for approximately 24 hours.   
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Table 3.  Ligation mixture volumes for DHFR-TS gene with pET-45b plasmid.  The 
ligation was performed with two different volumes of pET-45b plasmid and PCR material 
as the optimal amount of each needed for ligation was unknown.  The sample labeled 
DHFR-TS 1 contained 8 L PCR material, while the sample labeled DHFR-TS 2 
contained 4 L PCR material. 
 
DNA TRANSFORMATION IN E. COLI 
Once the ligation was complete, the DHFR-TS gene should have been inserted 
into the plasmid (referred to as ligation mixture).  To transform E. coli to express the 
gene to be used for protein expression, 50 µL of methyltransferase deficient, chemically 
competent E. coli cells suitable for replication of a plasmid free of Dam and Dcm 
methylation (dam-, dcm- E. coli cells; New England BioLabs) were added to a 14 mL 
polystyrene test tube with a lid (Fisher Brand, Fisher).  Five µL of the ligation mixture 
(DHFR-TS 1, DHFR-TS 2, or Control – No DHFR-TS from Table 3) was added and 
incubated on ice for 30 min, placed in a 42°C water bath for 30 sec, and placed back on 
ice for 2 min.  One mL of Lysogeny Broth (LB) medium (GeneMate, LB Miller Broth 
Powder) was added and the mixture was incubated with agitation (225 rpm) at 37°C for 
30 min.  The cells were centrifuged (Force Micro, Force1618) for 1 min, 10,000 rpm 
(8,944x g) in a microcentrifuge (Fisher Brand, 1.5 mL polypropylene) tube to pellet the 
cells, which were re-suspended in a minimal volume (50-100 µL) of LB medium.  The 
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suspension was dispersed onto an LB agar plate containing 100 µg/mL ampicillin and 
the cells were allowed to grow overnight at 37°C while shaking at 225 rpm.  Colonies 
that grew were assumed to contain the ampicillin resistance provided by retaining the 
pET-45b plasmid containing the DHFR-TS gene.   
 To grow large amounts of the cells that should contain the plasmid, a single 
colony of cells was removed and added to 2 mL of LB medium in a polystyrene test tube 
(Fisher Brand, Fisher) with lid containing 100 µg/mL ampicillin per 1 mL of LB medium.  
These were allowed to grow overnight at 37°C with 225 rpm agitation.  The DNA from 
these cells was purified using the Wizard Plus SV Miniprep DNA Preparation System kit 
(Promega). 
 A digestion, as described above (Table 2) using BamHI and HindIII restriction 
enzymes, was performed on the purified DNA and agarose gel electrophoresis was 
used to confirm the plasmid contained a DHFR-TS gene.  The DHFR-TS gene consists 
of approximately 1500 base pairs. 
 
PROTEIN EXPRESSION IN E. COLI 
 For protein expression, 1 µL of purified plasmid DNA containing the DHFR-TS 
gene was added to 50 µL of rare codon isoleucine, proline, leucine (RIPL) E. coli cells 
(Agilent Technologies), and the DNA transformation procedure, as previously 
discussed, was used to transform the plasmid into the RIPL E. coli.  RIPL E. coli cells 
are often necessary for expression of genes that contain rare codons for isoleucine, 
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proline, and leucine that are more common in non-E. coli species.  The cells were 
allowed to grow for 1 hour at 37°C with agitation (225 rpm) and were dispersed onto an 
agarose plate containing 100 µg/mL ampicillin (AMP) and 34 µg/mL chloramphenicol 
(CM).  The agarose plate was incubated at 37°C overnight.  Any colonies that grew 
were assumed to contain the plasmid with the DHFR-TS gene insertion.   
 A single colony was removed from the plate and placed in 5 mL of LB media 
containing 100 µg/mL AMP and 34 µg/mL CM.  After 24 hours of growth at 37°C and 
225 rpm agitation, these cells were transferred to 50 mL LB containing 100 µg/mL AMP 
and 34 µg/mL CM and allowed to grow for 3 hours at 37°C, 225 rpm.  Finally, the 50 mL 
cell growth was transferred to 1200 mL LB media containing 100 µg/mL AMP and 34 
µg/mL CM and grown at 37°C, 225 rpm for 24 hours.  A 1 mL sample was removed for 
sodium dodecyl sulfate-polyacrylamide gel electrophoresis (SDS-PAGE) analysis.  To 
the rest of the cells, 0.0500 g of isopropyl β-D-1-thiogalactopyranoside (IPTG) was 
added for a final concentration of 0.175 mM.  After 3 hours of growth, the cells were 
pelleted in 250 mL aliquots by centrifugation (5000x g for 5 min, Beckman, Avanti         
J-25 I).  Cells were re-suspended in 50 mM Tris, 100 mM NaCl pH 7.5 buffer as 20 mL 
aliquots and stored/frozen in 50 mL conical tubes (Corning, polypropylene centrifuge 
tubes).   
PROTEIN EXTRACTION AND PURIFICATION 
 To harvest the recombinant protein, the frozen cell pellet was placed on ice to 
thaw and 500 µL protease inhibitor cocktail (Sigma) was added.  The protease inhibitor 
cocktail consists of 2 mM 4-(2-Aminoethyl)benzensulfonyl fluoride hydrochloride 
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(AEBSF), 0.3 µM Aprotinin, 116 µM Bestatin, 14 µM E-64, 1 µM Leupeptin, and 1 mM 
EDTA 54, all of which inhibit different classes of proteases.  A French Pressure Cell 
Press (Spectronic Instruments, SLM-AMINCO) was used to lyse the cells at 10,000 psi 
to release soluble proteins.  The lysed material (crude extract) was collected and 
centrifuged at 31,000x g for 20 min at 4°C.  A sample of the pre-centrifuged material 
and a sample of the supernatant were saved for SDS-PAGE analysis.  The supernatant 
was collected for protein purification and the pellet was saved for protein analysis.   
 An affinity column was prepared using TALON® metal affinity resin, a cobalt 
containing resin.  Approximately 3 mL of resin was added to a column and equilibrated 
with approximately 45 mL of Tris buffer (50 mM Trizma, 150 mM NaCl, pH 7.5).  The 
supernatant was applied to the column and material that passed through the column 
was collected (column flow-through).  Because of the His-tag present on the amino 
terminal of the recombinant protein, it was expected that any expressed DHFR-TS 
protein would bind to the cobalt column due to Lewis acid-Lewis base interactions.  The 
column was washed with approximately 45 mL Tris buffer, to remove non-adhered 
protein in the column, and this was collected.  Approximately 20 mL of Tris buffer 
containing 10 mM imidazole was added to the column to remove (wash) any loosely 
bound protein by competitive binding of imidazole to the resin; the wash was collected.  
Finally, 10 mL of Tris buffer containing150 mM imidazole was added, and 1 mL fractions 
were collected in microcentrifuge tubes.  The 150 mM imidazole buffer was expected to 
remove any DHFR-TS tightly bound to the resin by the His-tag.   
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BIO-RAD ASSAY FOR PROTEIN CONCENTRATION DETERMINATION 
 The Bio-Rad reagent (Bio-Rad) was used for protein concentration determination 
in each fraction collected.  The Bio-Rad Protein Assay causes a shift in absorbance 
from 465 nm to 595 nm when the reagent-dye is bound to protein. 55  A standard protein 
curve was developed using known concentrations of bovine serum albumin (BSA) and 
absorbance was measured at 595 nm.  The following table (Table 4) was used to 
develop the standard protein curve (provided by J. Walker, Jan., 2015), while Figure 12 
shows the standard curve and linear equation.   
 
 
Table 4. Data for standard BSA protein curve provided by J. Walker. 
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Figure 12. Standard protein curve for protein concentration determination.   
 
Table 5 shows the volumes from each fraction used for protein determination.  
The absorbance was then measured at 595 nm using visible spectroscopy (Hewlett 
Packard, 8453 UV-Vis Spectrometer).  Protein concentration was determined based on 
a standard absorbance as a function of concentration of bovine serum albumin (BSA) 
curve with the line equation y = 0.0388x + 0.0224, where “y” is absorbance at 595 nm 
and “x” is the apparent protein mass (µg).  Protein concentration was calculated by 
dividing the amount of protein by the volume used in the assay.   
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Table 5. Volumes of reagents used for Bio-Rad protein assay.  Per the product 
information from Sigma-Aldrich, solutions containing less than 200 mM imidazole and 
2.0 M Tris do not interfere with absorbance at 595 nm. 56 
 
SDS-PAGE PROTEIN ANALYSIS 
 Sodium dodecyl sulfate-polyacrylamide gel electrophoresis (SDS-PAGE) was 
used to evaluate samples for protein expression using the general method of    
Laemmli. 57  DHFR-TS was expected to have a molecular weight of approximately 60 
kilo-Daltons (kDa).  Using gel electrophoresis, proteins in a sample can be separated 
based on apparent molecular weight.   
 SDS running gels were prepared by mixing 2.15 mL deionized (DI) water, 1.5 mL 
40% acrylamide (Sigma), 1.75 mL 1.5 M Tris pH 8.8 buffer, 0.05 mL 10% (w/v) SDS, 
10% (w/v) freshly made ammonium persulfate (APS), and 2 µL 
tetramethylethylenediamine (TEMED) (Sigma).  This mix was quickly pipetted between 
the glass plates of an SDS-PAGE mold apparatus (Bio-Rad, Mini PROTEAN® System 
Glass Plates) as the protein resolving gel.  Isopropanol was added to create a level 
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interface for the stacking gel portion.  Once the protein resolving gel polymerized, the 
isopropanol was removed and the stacking gel, consisting of 1.5 mL DI water, 0.25 mL 
40% acrylamide, 0.25 mL 1 M Tris pH 6.8 buffer, 0.02 mL 10% SDS, 20 µL APS, and 2 
µL TEMED, was added and the well comb was inserted.  SDS gels were typically made 
in batches of 2-4 and were stored in 1x SDS-buffer solution at 5°C for later use.  
 SDS-PAGE protein samples were prepared with no more than 15 µg of protein 
for non-purified samples and no more than 2.5 µg of protein for purified samples to be 
loaded on the gel.  The appropriate volume of protein solution and 4 µL 4x SDS dye 
were combined, with Nanopure water being added to a final volume of 20 µL.  Pellet 
samples were resuspended in 20 µL 1x SDS dye.  The samples were boiled for 5 min to 
denature the proteins before loading.  Precision Kaleidoscope Standard (Bio-Rad, 
Precision Plus ProteinTM KaleidsocopeTM Prestained Protein Standards; 5 µL) was used 
to evaluate protein molecular weights (Figure 13).  The 1x SDS-PAGE Running Buffer 
(25 mM Trizma, 250 mM glycine, 0.1% (w/v) SDS, pH 8.3) was added to the SDS-
PAGE chamber.  Then, 150 V was applied and the current was allowed to pass through 
the gel until the blue dye front ran off the gel.  Coomassie blue stain was used to 
visualize the protein bands, and de-stain, composed of 45% methanol, 10% acetic acid, 
and 45% water (v/v/v), was applied to remove stain from regions of the gel devoid of 
proteins.  Gels were preserved by lamination as necessary. 
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Figure 13.  Precision Plus ProteinTM KaleidsocopeTM Prestained Protein Standards. 58 
 
DHFR ENZYME ACTIVITY ASSAY 
 In a UV transparent cuvette, purified L. major DHFR-TS protein was incubated 
with 400 µM final concentration NADPH (Sigma) in pH 6.5 Tris, 150 mM imidazole 
buffer at room temperature, after blanking with pH 6.5 Tris, 150 mM imidazole buffer.  
After approximately 5 min of incubation, 50 µM final concentration dihydrofolic acid was 
added.  Absorbance was measured at 340 nm utilizing the kinetic mode (Hewlett 
Packard 8453 UV-Vis spectrophotometer, HP 8453A software).  Because NADPH 
absorbs at 340 nm, if the DHFR-TS enzyme is active, a reduction in absorbance at that 
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wavelength would be expected with the oxidation of NADPH to NADP+ in a 
stoichiometric reduction of dihydrofolate to tetrahydrofolate. 59    
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CHAPTER III 
RESULTS AND DISCUSSION 
LEISHMANIA GROWTH CURVES WITH AND WITHOUT SULFONAMIDES 
 The promastigote form of axenic Leishmania tarentolae was grown to the log 
phase of the growth curve (day 2) then treated with a 100 µM concentration of three 
sulfonamides (Figure 14):  N-(2’-methylthiophenyl)-1-napthalne sulfonamide 
(Compound A), N-(2’-methoxyphenyl)-1-napthalene sulfonamide (Compound B), and N-
(2’-methylphenyl)-1-napthalene sulfonamide (Compound C) (provided by Dr. Hamaker).   
 
 
Figure 14. Chemical structures of N-(2’-methylthiophenyl)-1-napthalene sulfonamide 
(Compound A), N-(2’-methoxyphenyl)-1-napthalene sulfonamide (Compound B), and N-
(2’-methylphenyl)-1-napthalene sulfonamide (Compound C). 
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Upon addition to cells grown in BHI, water solubility issues were seen at this 
concentration for the three sulfonamides with crystals forming within 24 hours after 
addition.  Significant inhibitory effects on cell viability were seen with a 100 µM addition 
of Compound C, but were not seen with the other two sulfonamides (Figure 15).  Within 
24-48 hours after addition of Compound C, an 85-95% reduction in cell viability was 
observed.  Cells transferred to fresh medium were unable to recover over three days, 
which was an indication of cell death.  
      
 
Figure 15.   MTT cell viability results after addition of 100 µM sulfonamides for 
representative experiment. One percent DMSO was added to control cells. Values are 
the mean ± standard deviation for n = 4 replicates. 
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Microscopy was also used to evaluate the cells in the presence of the 
sulfonamides.  Addition of 100 µM Compound C caused cells to maintain typical shape, 
but, per the MTT cell viability assay, lose viability.  This is different than typical 
senescence phase cell death, which is visually characterized by cells becoming 
spherical in shape.  This effect on cell shape was noted for each 100 µM Compound C 
experiment.  Compounds A and B did not negatively affect viability or motility, whereas 
cells lost motility in the presence of Compound C.  It appeared that Compounds A and B 
had a positive effect on the Leishmania, increasing the viability and extending the 
culture lifetime relative to control cells. 
Because of the water solubility issues with Compound C, it was not possible to 
know the effective concentration (EC50) of Compound C that caused negative cell 
responses.  To determine if lower concentrations could provide similar results 10 µM or 
50 µM concentrations of Compound C were added to cell culture and these cells were 
evaluated for viability.  As seen in Figure 16, lower concentrations of Compound C did 
not have the same inhibitory effect without recovery over time.  The 10 µM 
concentration appeared to have an activating effect on cells, more like that seen for 
Compounds A and B.  The 50 µM concentration appeared to have some negative effect 
on cell viability, but crystal formation was still seen within 24 hours of addition, meaning 
the cells were likely not exposed to the full 50 µM concentration.   The water solubility 
issues also prevented multi-day compound additions.   
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
Figure 16. MTT cell viability of cells with 10 µM, 50 µM, or 100 µM additions of 
Compound C. One percent DMSO was added to control cells.  Values are the mean ± 
standard deviation for n = 4 replicates. 
  
SYNTHESIS OF WATER SOLUBLE STRUCTURAL ANALOGS AND INHIBITION 
TESTING 
Because insolubility of compounds in water can affect how cells access and 
utilize compounds, water solubility can be an important characteristic for therapeutics.  
When compounds re-crystalize in the growth medium, the optimal treatment 
concentration cannot be easily evaluated and multiple doses cannot be utilized.  To 
address the water solubility concerns seen with the most inhibitory compound, two 
water-soluble analogs of Compound C were synthesized (Figure 17).  Because the 
group ortho to the amide in Compounds A, B, and C differentiated between cellular 
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inhibition, a structural analog of Compound C with a carboxyl group para to the amide 
was synthesized (Compound D) and a second compound without the functional group 
at the 2’-phenyl position but with a carboxyl para to the amine (Compound E) was also 
synthesized and characterized.    
 

Figure 17.  Chemical structures of N-(2’-methylphenyl)-(4-carboxyl)-1-napthalene 
sulfonamide (Compound D) and N-(4-carboxyl)-1-napthalene sulfonamide (Compound 
E). 
 
 
 Compounds D or E were added to cells at 100 µM concentrations and cell 
viability was evaluated with an MTT assay.  The results in Figure 18 were plotted as a 
percentage of control cells (1% DMSO added), and show Compound E had only modest 
inhibition of cell viability and was only tested for 2 days after addition, while Compound 
D had some inhibitory effect on cell viability at days 1-3 after addition (approximately 
70% inhibition) with viability recovery four days after addition.  Where results were 
compared to Compound C, less inhibition and more apparent cell recovery was 
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observed over the 4 days, unlike results with Compound C (approximately 90-96% 
inhibition without recovery).  However, because Compound D is water soluble, multiple 
additions of the compound can be applied to the cells.   
 
 
Figure 18. Cell viability as a percent of control cells in the presence of 100 µM 
Compound C, D, or E. Values are the mean ± standard deviation for n = 4 replicates. 
 
To determine if inhibitory effects could be accumulative for Compound D, two 
sequential doses of 50 µM Compound D were added to cells and evaluated for effect on 
'
'
'
'
'
	'

'
'
'
'
'
   


!!
?
#

#!
#




,












!

!!
; ###
!!?##!#,!!!#&,
5 337


7
43 

cell viability.  As seen in Figure 19, two sequential doses of 50 µM Compound D were 
equivalent on day 5 to a single 100 µM addition of Compound D.   
 
 
Figure 19.  Representative growth curve showing the impact of two doses of 50 µM 
Compound D added on day 3 and day 4 on cell viability compared to single dose of 100 
µM Compound D added on day 3. One percent DMSO was added to control cells. 
Values are the mean ± standard deviation for n = 4 replicates.  
 
 
When evaluated by microscopy, the cells treated with Compound D had a 
difference appearance than those treated with Compound C.  Cells treated with 
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Compound C appeared to maintain a typical cell shape but with greatly reduced motility, 
though MTT cell viability results indicated cell inhibition.  Cells treated with Compound D 
presented a cell shape more similar to typical senescence.  The visual difference in 
cells after treatment implies different pathways of inhibition for these two sulfonamides.  
Half maximal effective concentration (EC50) is the concentration of a treatment 
that induces a response that is 50% of the maximum response after a specific exposure 
time.  EC50 was calculated for Compound D by plotting the percent cell viability (percent 
of control cells) after 24 hours of exposure as a function of concentration added.  As can 
be seen in Figure 20, the EC50 was determined to be approximately 74 M for this study. 
 
Figure 20.  Determination of approximate EC50 for Compound D. EC50 was calculated 
to be approximately 74 M.  
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EFFECTS OF FOLATE ON CELL VIABILITY WITH AND WITHOUT 
SULFONAMIDES 
 Sulfonamides are known inhibitors of dihydrofolate reductase (DHFR), an 
enzyme in the folic acid cycle of bacteria, preventing folate from being reduced to 
dihydrofolate and dihydrofolate from being reduced to tetrahydrofolate. 7  To determine if 
Compounds C or D could be inhibitors of DHFR, 100 µM folic acid and 100 µM 
Compound C or D were added to cells in the log phase and evaluated for cell viability 
compared to control cells.   
As can be seen in Figure 21, addition of an equivalent concentration of folic acid as 
Compound C provided approximately 50% more cell viability than cells treated with 
Compound C alone.  However, cells treated with an equivalent amount of folic acid and 
Compound D did not exhibit protection.  This also indicates the likelihood of different 
pathways of inhibition for these two sulfonamides.  A Students two tail statistical t-test, 
where p < 0.05 is considered significant, confirmed that mean cell viability as a percent 
of the control cells indicated statistically different responses with the addition of 
Compound C only or Compound C with 100 µM folic acid.  However, there was no 
statistical difference with the addition of Compound D only or Compound D with 100 µM 
folic acid. 50      
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Figure 21. Effects of folic acid or folic acid with Compound C or D on cell viability as a 
percent of control cells. Values are the mean ± standard deviation for n = 4 replicates. 
 
 
RECOMBINANT DHFR-TS EXPRESSION AND EVALUATION 
To evaluate the effects of the sulfonamide inhibitors on DHFR function, 
recombinant DHFR-TS from L. major was expressed, extracted, purified, and activity 
evaluated by measuring the rate of NADPH oxidation to NADP+.  Using PCR, 
recombinant DNA for L. major DHFR-TS was synthesized.  Agarose gel electrophoresis 
suggested the recombinant DNA contained the proper number of base pairs expected 
for the gene.  The nucleotide sequence of the DHFR-TS gene, containing 1563 
nucleotides, is shown in Figure 22. 51   
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5’- 
atgtccagggcagctgcgaggtttaagattccgatgccggagacgaaggcagactttgctttcc
cctccctgcgcgccttctccatcgtcgtggccctcgatatgcagcacggcatcggcgacggcga
gtcgatcccgtggcgggtgccggaggacatgacgtttttcaagaaccagacgacgctgctgcgc
aacaagaagccgccgacggagaagaagcgcaacgccgtcgtgatgggccgcaagacttgggaga
gcgtcccggtaaagttccgaccactcaagggacggctgaacatcgtgttatcctcgaaggccac
cgtcgaggagcttctggcgccgctgccggagggacagcgcgcggcggcggcgcaggatgtggtg
gtggtgaacggcggtctggccgaggcgctccgcctcctcgcacgcccgctgtactgcagctcca
tcgagacagcgtattgcgtcggtggtgcgcaggtttacgcggacgccatgctgtcgccgtgcat
cgagaaactgcaggaagtgtacctgacccgcatctacgcgacggcgcctgcgtgtacgcgcttc
tttccgtttccgcccgagaacgcggccacggcgtgggacctggcgtcgtctcagggacgccgca
agagcgaggcggagggcctcgagttcgagatctgcaagtacgtgccgcgcaaccacgaggagcg
gcagtaccttgagctgattgaccgcatcatgaagacggggatcgtgaaggaggaccgcaccggc
gtgggcaccatcagcctcttcggcgcccagatgcgcttctccctacgcgacaaccgcctgccgc
tgctgacgacgaagcgtgtcttctggcgcggcgtgtgcgaggagctgctgtggttcctgcgcgg
ggagacgagtgcgcagctgctggcagacaaggacattcacatctgggacggcaacggttcgcgc
gagtttctcgacagccgcggcttgacagagaataaggagatggacctcggccctgtctacggct
tccagtggcgccacttcggggcagattacaaggggtttgaagcgaactacgacggcgaaggggt
ggaccagatcaagctcatcgtggagaccatcaagacgaacccgaacgaccgccgcctcctagtc
actgcctggaacccgtgcgcgctgcaaaagatggcgctgccgccgtgccacttgcttgctcagt
tctacgtgaacacagacacgagcgagctatcctgcatgttgtaccagcgctcgtgtgacatggg
tcttggcgtccccttcaacattgcctcctacgcgctgctcaccatcctcattgccaaggcgacg
ggtctgcggcctggtgagcttgtgcacaccctcggcgacgcccacgtctaccgcaaccacgttg
atgccctcaaggcgcagctcgagcgagtcccgcacgcgttcccgaccctcatcttcaaggagga
gcggcagtacctcgaggactacgagttgacggacatggaggtgatcgactacgttccacacccg
gcgatcaagatggagatggccgtatag – 3’ 
 
Figure 22. Nucleotide sequence for the coding single strand of the L. major DHFR-TS 
gene. 51 
 
 
 
 The agarose gel electrophoresis for the digested pET-45b plasmid and the 
recombinant DHFR-TS gene are shown in Figure 23.  The DNA bands (circled in lanes 
2 and 3) were cut from this gel for the pET-45b plasmid (lane 2) and DHFR-TS gene 
(lane 3) for ligation.   
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Figure 23. Agarose gel electrophoresis of digested pET-45b and recombinant DHFR-
TS gene used for ligation.  Lane 1 is the standard 1 kb Ladder, lane 2 is the digested 
pET-45b plasmid, and lane 3 is the digested recombinant DHFR-TS gene. 
 
 After ligation, to ensure the DHFR-TS gene was inserted into the plasmid and 
expressed in the dam- dcm- E. coli cells, a BamHI and HindIII digestion was performed 
on the purified DNA and an agarose gel was used to evaluate the digested components.  
The agarose gel is shown in Figure 24.  The gel provided evidence that the gene was 
inserted into the pET-45b plasmid and could be transformed into E. coli cells to express 
protein.   
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Figure 24.  Agarose gel electrophoresis of digested plasmid DNA from dam- dcm- E. 
coli.  Lane 1 is the standard 1 kb ladder and lane 2 is the digested pET-45b plasmid 
containing the DHFR-TS gene.   
 
 The concentration of the purified DNA, pET-45b with inserted recombinant 
DHFR-TS gene was determined using a NanoDrop 2000c Spectrophotometer 
(ThermoScientific) by measuring absorbance at 260 nm.  The estimated concentration 
was found to be 25 ng/L.  Samples of the DNA were sent to the University of Illinois 
Urbana-Champaign (UIUC) Core Sequencing Facility in Urbana, IL for DNA sequencing 
from the promoter and terminal ends of the DNA for a more accurate output.  The data 
from UIUC can be seen in Appendix C.  Some nucleotides in both sequences could not 
be assigned automatically by the software, but manual review of the raw trace allowed 
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for some nucleotides to be replaced with the most likely option.  An example trace is 
shown in Appendix D.   
 A Basic Local Alignment Search Tool (BLAST) search was performed to identify 
regions of similarity between the gene sequencing provided by UIUC and a vast 
database of nucleotide sequences from various species. 60  It is important to note that 
most sequencing methods can become less reliable around 700 nucleotides, so it is 
important to evaluate both the promotor and terminal directions of the DNA of interest.  
A 96% agreement was identified between nucleotides 190-816 of the sequenced 
promoter DHFR-TS gene and the sequence from which the primers were designed, 
Sequence ID M12734.1. 51  After the terminal sequence of the DHFR-TS gene was 
reversed and converted to its complimentary nucleotides, 97% agreement was found 
between nucleotides 399-1269 of the sequenced terminal DHFR-TS gene and the 
sequence from which the primers were designed. 51  However, 395 nucleotides of the 
recombinant DHFR-TS gene were inadequately sequenced.  Two additional primers 
were designed to allow for more accurate sequencing of those nucleotides and data 
was, again, acquired from UIUC.  The alignments are shown in Appendix E.   
 The sequenced data were combined, based on the alignment data, and the 
nucleotide sequences were translated to amino acids using the translation software 
from ExPasy. 61  Amino acid alignments were performed between the translated DNA 
sequences from the promoter and terminus gene sequences and DHFR-TS from          
L. major (M12734) 51 using Kalign Multiple Sequence Alignment 62 and BoxShade 
software. 63  The alignment is shown in Figure 25.  There was 100% alignment between 
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the amino acid sequences of the L. major DHFR-TS from the Gene Bank and the 
recombinant L. major DHFR-TS. 
DHFRTS        1 MSRAAARFKIPMPETKADFAFPSLRAFSIVVALDMQHGIGDGESIPWRVPEDMTFFKNQT 
SeqRecGene    1 MSRAAARFKIPMPETKADFAFPSLRAFSIVVALDMQHGIGDGESIPWRVPEDMTFFKNQT 
 
DHFRTS       61 TLLRNKKPPTEKKRNAVVMGRKTWESVPVKFRPLKGRLNIVLSSKATVEELLAPLPEGQR 
SeqRecGene   61 TLLRNKKPPTEKKRNAVVMGRKTWESVPVKFRPLKGRLNIVLSSKATVEELLAPLPEGQR 
 
DHFRTS      121 AAAAQDVVVVNGGLAEALRLLARPLYCSSIETAYCVGGAQVYADAMLSPCIEKLQEVYLT 
SeqRecGene  121 AAAAQDVVVVNGGLAEALRLLARPLYCSSIETAYCVGGAQVYADAMLSPCIEKLQEVYLT 
 
DHFRTS      181 RIYATAPACTRFFPFPPENAATAWDLASSQGRRKSEAEGLEFEICKYVPRNHEERQYLEL 
SeqRecGene  181 RIYATAPACTRFFPFPPENAATAWDLASSQGRRKSEAEGLEFEICKYVPRNHEERQYLEL 
 
DHFRTS      241 IDRIMKTGIVKEDRTGVGTISLFGAQMRFSLRDNRLPLLTTKRVFWRGVCEELLWFLRGE 
SeqRecGene  241 IDRIMKTGIVKEDRTGVGTISLFGAQMRFSLRDNRLPLLTTKRVFWRGVCEELLWFLRGE 
 
DHFRTS      301 TSAQLLADKDIHIWDGNGSREFLDSRGLTENKEMDLGPVYGFQWRHFGADYKGFEANYDG 
SeqRecGene  301 TSAQLLADKDIHIWDGNGSREFLDSRGLTENKEMDLGPVYGFQWRHFGADYKGFEANYDG 
 
DHFRTS      361 EGVDQIKLIVETIKTNPNDRRLLVTAWNPCALQKMALPPCHLLAQFYVNTDTSELSCMLY 
SeqRecGene  361 EGVDQIKLIVETIKTNPNDRRLLVTAWNPCALQKMALPPCHLLAQFYVNTDTSELSCMLY 
 
DHFRTS      421 QRSCDMGLGVPFNIASYALLTILIAKATGLRPGELVHTLGDAHVYRNHVDALKAQLERVP 
SeqRecGene  421 QRSCDMGLGVPFNIASYALLTILIAKATGLRPGELVHTLGDAHVYRNHVDALKAQLERVP 
 
 DHFRTS      481 HAFPTLIFKEERQYLEDYELTDMEVIDYVPHPAIKMEMAV 
 SeqRecGene  481 HAFPTLIFKEERQYLEDYELTDMEVIDYVPHPAIKMEMAV 
 
 
Figure 25.  Amino acid alignment of recombinant L. major DHFR-TS gene to DHFR-TS 
gene from L. major (Genebank ID: M12734). 51  DHFRTS identifies the amino acid 
sequence of the L. major gene from the gene bank (M12734) and the SeqRecGene 
identifies the amino acid sequence of the combined, sequenced recombinant L. major 
amino acid sequence. 
 
 Because a crystal structure of the bifunctional enzyme, DHFR-TS, from L. major 
does not currently exist, a crystal structure from Trypanosoma cruzi (Protein Data Bank 
ID: 3HBB) 64 was used instead for identification of amino acids important to the active 
site and activity of the enzyme.  Figure 26 shows the amino acid comparison of L. major 
and T. cruzi, where the amino acids believed to be associated with the active site are 
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highlighted in blue (dihydrofolic acid interaction) and red (NADPH interaction).  The 
DHFR portion of the two enzymes does not align completely, but the active sites within 
the enzyme do share common amino acids, making the T. cruzi crystal structure 
beneficial in evaluating mutations that may be seen in the sequencing data. 
 
Figure 26. Amino acid alignment of L. major and T. cruzi DHFR-TS.  Amino acids 
highlighted in blue were identified as binding to dihydrofolic acid and red were identified 
as binding to NADPH. 
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PROTEIN EXPRESSION, PURIFICATION, AND KINETICS ASSAYS 
 Once the DHFR-TS gene was inserted into the plasmid, the plasmid was 
transformed into competent RILP E. coli cells.  The protein was extracted, purified, and 
protein concentration was calculated for each fraction using a Bio-Rad Assay.  
Calculated protein concentrations are shown in Table 6.   
 
 
Table 6.  Calculated protein concentrations from protein purification. 
SDS-PAGE was used to determine if the DHFR-TS protein was expressed in the 
E. coli.  Aliquots from the lysate (crude extract), supernatant from the crude extract, 
column flow through, buffer wash, 10 mM imidazole wash, and 150 mM imidazole 
fractions from the cobalt affinity purification process were first evaluated for protein 
concentrations using the Bio-Rad assay for protein determination.  Based on the results 
for this work, the appropriate concentration of each aliquot was prepared and SDS-
PAGE was used to evaluate protein present, with specific interest in a band appearing 
at approximately 60 kD.  The molecular weight of DHFR-TS is 58,689 g/mol without the 
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His-tag and 59,511 g/mol with the His-tag.  A representative gel with expressed protein 
at the approximate molecular weight for DHFR-TS is shown in Figure 27. 
 
Figure 27. SDS-PAGE gel of crude lysed cells, column flow through, buffer wash, 10 
mM imidazole wash, and 150 mM fractions containing protein.  The DHFR-TS enzyme 
has a molecular weight of 59,511 g/mol (60 kD) with the His-tag.  A band was identified 
at approximately 60 kD, indicating DHFR-TS was likely extracted and partially purified.   
  
Because DHFR-TS is soluble and should contain a His-tag, the band shown in 
the fractions of 150 mM imidazole were expected to be the protein of interest.  Fractions 
containing the protein of approximately the correct molecular weight of DHFR-TS were 
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evaluated for enzyme kinetic activity.  The assay for DHFR activity involved measuring 
the absorbance reduction at 340 nm as NADPH was oxidized to NADP+ in the presence 
of dihydrofolic acid.  For all column fractions obtained in this experiment, enzyme 
assays were performed, but no catalytic activity was detected.   
 One possible reason for lack of enzyme activity could be instability of the DHFR-
TS bifunctional enzyme.  Studies to characterize the bifunctional DHFR-TS of 
Trypanosoma brucei, another protozoan parasite, have shown instability of the DHFR-
TS complex typically caused by the more insoluble TS region of the protein. 65  To 
improve the stability of the bifunctional enzyme, the authors used an E. coli elongation 
factor, Ts, which was designed upstream of the His-tag.  The addition of this elongation 
factor improved protein stability and allowed for activity of the DHFR and TS portions of 
the protein. 65  Elongation factors are proteins used in the synthesis of proteins and are 
present in large quantities in cells to help elongate peptide chains.  Ts is a guanine-
nucleotide exchange factor that catalyzes mediation of the displacement of a byproduct 
of elongation, guanosine diphosphate (GDP), by Tf (a highly abundant elongation 
factor).  Then guanosine triphosphate (GTP), an energy source necessary for the 
peptide bond formation 66, is inserted allowing for potential improvement in protein 
solubility. 
 Lack of enzyme activity could also be due to protein misfolding.  Chaperonins are 
proteins found in all cells that help fold proteins into their proper three-dimensional 
structure.  GroEL and GroES are E. coli chaperonins that have been well characterized 
and studied, and have been found to help fold proteins which is accompanied by the 
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hydrolysis of adenosine triphosphate (ATP). 67  Chaperonins may work well with many 
proteins. However, when E. coli are forced to grow quickly and exhibit high protein 
expression, there is more opportunity for misfolding of heterologous proteins.  Using a 
strain of E. coli that grows at low temperatures can improve the accuracy of folding 
activity in the cells.  The E. coli strain, ArcticExpress competent cells, improves protein 
folding as the cells also express cold-temperature chaperonins Cpn10 and Cpn60. 68  
Use of ArcticExpress cells can increase the amount of active, soluble protein present, 
improving the possibility of enzyme activity.   
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CHAPTER IV 
CONCLUSIONS AND FUTURE WORK 
SULFONAMIDE EFFECTS ON LEISHMANIA PROMASTIGOTE VIABILITY 
Promastigote and amastigote forms of Leishmania differ by shape, motility, and 
gene expression.  The amastigote form of the parasite is commonly found in a 
phagocytic cell, such as the macrophage, of the vertebrae host, while the promastigote 
form is considered the infective form of the parasite.  Targeting the promastigote form of 
the life cycle could provide prevention of further infection of phagocytic cells and be an 
effective mechanism of treatment for the different forms of leishmaniasis.   
In this study, newly synthesized sulfonamides and water-soluble analogs were 
evaluated for their inhibitory effects on the growth and viability of Leishmania tarentolae 
promastigotes.  N-(2’-methylphenyl)-1-napthalene sulfonamide (Compound C) was 
seen to inhibit cell viability 90-96% 24 hours after 100 M addition, though crystallization 
was seen in the medium and effective concentration (EC50) was not able to be 
determined. Other sulfonamides tested in this experiment, N-(2’-methylthiophenyl)-1-
napthalene sulfonamide (Compound A) and N-(2’-methoxyphenyl)-1-napthalene 
sulfonamide (Compound B), with larger, more electronegative groups ortho to the amine 
group, exhibited no negative effect on cell viability or acted as a vitamin to the parasites, 
improving cell viability.  These data provide insight into the interaction of the 
sulfonamide with the inhibitory target (enzyme, transport protein, or other), in that the 
small, non-polar functional group ortho to the amine must have some important 
interaction that affects function of the target.   
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The differences that structural changes have on inhibitory effects could also be 
seen with the addition of a carboxyl group para to the amine group.  The water-soluble 
analog, N-(2’-methylphenyl)-(4-carboxyl)-1-napthalene sulfonamide (Compound D), 
exhibited approximately 70% cell viability inhibition after 24 hours with 100 M addition, 
while the water-soluble analog without a methyl group para to the amine group exhibited 
only approximately 30% inhibition with one addition of 100 M.  Furthermore, 
differences in cell behavior were also documented.  Cells treated with 100 M 
Compound C appeared to be paralyzed 24 hours after treatment, as microscopy 
indicated cells were without movement but maintained the promastigote cell shape.  In 
contrast, cells evaluated 24 hours after treatment with 100 M Compound D appeared 
to lose their flagella and were more circular in shape, a cellular change more commonly 
associated with cell death; however, both samples of cells were transferred to fresh 
medium and little to no cell recovery was noted.  This observation leads to the 
assumption that there is a difference in inhibitory mechanism between the two 
compounds. 
Because Compound C was insoluble in the cellular medium at concentrations 
from 10 M to 100 M, an EC50 value could not be determined.  However, the EC50 
value for Compound D obtained and compared to those previously reported 7 as seen in 
Table 7.  The EC50 values show that a lower concentration of Compound D, with a 
shorter exposure time, is a more effective anti-leishmanial compound compared to other 
compounds reported by Peixoto and Beverley. 7  
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Table 7.  Comparison of EC50 values for previously published compounds compared to 
N-(2’-methylphenyl)-(4-carboxyl)-1-napthalene sulfonamide (Compound D).  All EC50 
values were reported after 48 hours exposure 7, except for Compound D, which was 
calculated after 24 hours of exposure (* this thesis).   
 
 Peixoto and Beverley also reported that folate addition in the presence of the 
sulfonamides tested did not affect inhibition, which was different from the results of 
Compound C from this study, but not with Compound D.  This, again, enforces the 
potential differences in mechanism of inhibition between the two tested compounds and 
possibly a different pathway of inhibition between Compound C and the sulfonamides 
tested by Peixoto and Beverley. 7 
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 Because Compound D is water-soluble, sequential treatments can be added to 
the cells with accumulative inhibition.  Experimentation showed that the addition of two 
50 M concentrations of Compound D over 48 hours exhibited equivalent cell viability 
inhibition compared to one 100 M addition 24 hours after exposure.  Additive inhibitory 
effects could be beneficial as a treatment, allowing lower doses to be given to a patient 
to reduce potential side effects and/or manage toxicity to the patient.   
 Current treatments utilize varying treatment doses that have been shown to 
inhibit Leishmania promastigotes.  Amphotericin B exhibited 100% inhibition of L. 
donovani promastigotes with addition of 0.3 M 69, which was scaled-up to 0.75-1 mg/kg 
doses applied daily for 15-20 days for human trials. 70  However, at this treatment rate, 
side effects can be severe and close monitoring is necessary, leading to increased cost 
of therapy.  Miltefosine required a 10 M dose to inhibit 66% of L. donovani 
promastigotes after 48 hours. 71  In human studies, 50-100 mg doses were required over 
28 days for a 94% cure rate, but, it is important to note, that the long half-life makes the 
compound vulnerable to drug resistance and the cost and need for monitoring makes 
the treatment expensive. 70  Antimonial drugs, like glucantime, have been shown to 
inhibit L. braziliensis and L. guyanensis in a dose-dependent manner over 
concentrations of 0.23-23 mM. 72  Human treatments require 20 mg/kg doses over 28-30 
days 73; however, again, side effects such as cardiotoxicity, renal failure, and 
pancreatitis, as well as reduced responsiveness to these treatment types have affected 
its use. 9  In comparison, N-(2’-methylphenyl)-(4-carboxyl)-1-napthalene sulfonamide 
could allow for a novel approach to treatment with potential for reduced parasitic 
resistance.  As a water-soluble compound, it has the ability to be administered as a 
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topical agent, orally, or intravenously, once the pathway and mechanism of inhibition is 
more thoroughly evaluated. 
 
DHFR-TS PATHWAY EVALUATION 
 Agarose gel electrophoresis confirmed that the approximate size of the L. major 
DHFR-TS gene was inserted into the pET-45b plasmid.  The plasmid was transformed 
to competent RILP E. coli and, after protein purification, SDS-PAGE confirmed the 
approximate protein size was eluted from the affinity column.  However, the DHFR 
portion of the enzyme has provided no measurable catalytic activity.  The lack of activity 
could be due to enzyme instability caused by the more unstable TS portion of the 
bifunctional enzyme or by misfolding of the protein within the RILP E. coli used for 
protein expression.   
 Gene sequencing performed at UIUC confirmed the recombinant gene matches 
the L. major gene from which the primers were designed near the beginning and end of 
the gene sequence, but was not accurately sequenced near the middle of the gene.  
Primers were designed and submitted to UIUC for more accurate sequencing of the 
gene, as there are 395 nucleotides that were not sequenced.  Because the recombinant 
gene aligns, it is likely a catalytically active form of the protein could be expressed. 
If the gene has been properly expressed, future work should include the 
expression of recombinant DHFR-TS in ArcticExpress cells, as growth at lower 
temperatures with different chaperonin proteins could improve protein folding.  If this is 
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not sufficient, it may also be beneficial to encode the Ts elongation factor into new 
primers, as this has been seen to improve the solubility of the TS portion of the enzyme.  
Expression of the DHFR portion of the bifunctional protein gene alone, without the TS 
portion of the enzyme, could also help express the catalytically competent DHFR 
enzyme for inhibition testing.  The primers for the DHFR gene have been designed, but 
the recombinant gene was not successfully expressed without the TS gene.  The 
method used to successfully ligate the recombinant DHFR-TS gene into pET-45b 
plasmid, in which the purified DNA was cut from the agarose gel after electrophoresis, 
purified, and used for ligation, should be used for future studies.  Understanding the 
effect of the inhibitory sulfonamide compounds on DHFR kinetics would be helpful in 
identifying pathways of inhibition for the Leishmania promastigotes, as well as better 
understanding potential side effects in the host.   
 
FUTURE WORK 
 Although a significant amount of work has been completed in the evaluation of 
sulfonamides synthesized at Illinois State University as inhibitors of Leishmania, there 
are still many areas of interest that should be investigated.  N-(2’-chlorophenyl)-1-
napthalene sulfonamide, previously tested by research students in the Jones lab (via 
personal communication), showed promising response at low concentrations (76% 
inhibition with 15 M addition, after 24 hours).  This compound was not available for 
these studies, but it would be very interesting to compare the inhibitory effects of this 
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compound with the inhibition demonstrated by Compounds C and D and what effects, if 
any, folate would have on the inhibition. 
 Also, because promastigotes and amastigotes are known to express different 
genes, testing the inhibitory effects of Compounds C and D on the amastigote forms of 
the Leishmania would help determine if the sulfonamides would inhibit both cellular 
forms, which could make for a potentially better treatment.  Previous work has shown 
axenic amastigotes are acceptable screening methods for anti-leishmanial treatments. 5  
This method should be used to evaluate Compounds C and D for inhibition of axenic 
amastigotes.  Testing with Leishmania that infect humans is also essential in insuring 
inhibitory effects seen with L. tarentolae are applicable to the human pathogenic 
species.  The sulfonamides of interest can be sent to collaborators in Colombia to 
perform this testing.   
 The folate pathway also involves other enzymes that could be evaluated in the 
presence of the inhibitory sulfonamides, including dihydropteroate synthase and 
pteridine reductase (PTR1).  Dihydropteroate synthase is reported to be inhibited by 
some sulfonamides. 31  To test the effects of the sulfonamides on inhibition, the 
recombinant genes could be expressed using dam- dcm- competent E. coli and 
recombinant protein expressed in either RILP E. coli or ArcticExpress cells.  The ability 
to inhibit PTR1 could be beneficial in inhibiting the amastigote form of the disease, as 
PTR1 has been reported to be more active in acidic environments such as that found in 
a phagocytic cell. 43  Also, because folate did not have an effect on the inhibitory 
performance of Compound D, evaluating the mechanism of inhibition for this compound 
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could be interesting.  Other pathways of inhibition that may be useful to investigate 
include inhibition of carbonic anhydrase 74 and disruption of cell proliferation by 
disruption of microtubule activity. 33 
 The promising effects of Compounds C and D for inhibition of L. tarentolae 
promastigotes at reasonable treatment concentrations within 24 hours indicates that 
these compounds may be good candidates for treatment of human infective species of 
Leishmania.  Additional work is necessary to understand the true potential of the 
compounds of interest, including testing the compounds in the human infective forms of 
the parasite, evaluating the compounds’ effects on the amastigote form of Leishmania, 
and identifying the pathway and mechanism of inhibition and developing a better 
understanding of potential effects in the host.  With so many people affected globally, 
the need to develop better treatments for leishmaniasis is necessary, and the 
compounds in this study could become prospective treatments with additional 
investigation.    
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APPENDIX A 
1H-NMR OF N-(2’-METHYLPHENYL)-(4-CARBOXYL)-1-NAPTHALENE 
SULFONAMIDE (COMPOUND D) 
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APPENDIX B 
1H-NMR OF N-(4-CARBOXYL)-1-NAPTHALENE SULFONAMIDE (COMPOUND E) 
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APPENDIX C 
RAW SEQUENCING DATA FROM UNIVERSITY OF ILLINOIS, URBANA-CHAMPAIGN 
(UIUC) 
Promoter Primer –  
NNNNGNTGNNNNNTNNNNNNTNNNNNGNNNCNNTNGGGNNNNNNNTGNNNNNNNNNNNNNNNNNNNNNNAGGGGGGA
ANTCCTNCACAAAATTTTGTTTACTTAAGAAGGAGATATACCANGGNACATCCCTCTTNAAAGGNCGCTGGGTACCG
GTTCGAATGATGACGACGACTAGAGNNCGGATCCCATGTCCAGGGCAGCTGCGAGGTTTAAGATTCCGATGCCGGAG
ACGAAGGCAGACTTTGCTTTCCCCTCCCTGCGCGCCTTCTCCATCGTCGTGGCCCTCGATATGCAGCACGGCATCGG
CGACGGCGAGTCGATCCCGTGGCGGGTGCCGGAGGACATGACGTTCTTCAAGAACCAGACGACGCTGCTGCGCAACA
AGAAGCCGCCGACGGAGAAGAAGCGCAACGCCGTCGTGATGGGCCGCAAGACTTGGGAGAGCGTCCCGGTAAAGTTC
CGACCACTCAAGGGACNNCTGAACATCGTGTTATCCTCGAAGGCCACCGTCGAGGAGCTTCTGGCGCCGCTGCCGGA
GGGACAGCGCGCGGCGGCGGCGCAGGATGTGGTGGTGGTGAACGGCGGTCTGGCCGAGGCGCTCCGCCTCCTCGCAC
GCCCGCTGTACTGCAGCTCCATCGAGACAGCGTATTGCGTCCGGTGGTGCGCAGGTTTACGCGGACGCCATGCTGTC
GCCGTGCATTCGAGNAAACTGCAAGGAAAGTGTACCTGGACCCGCATCTTACNCCGACGGCNGCCTGCGTNGTACGC
GCCTTCTTTTNCCGTTTTCCCGCCCCGAATAACGGCGGGCCNACGGGCNGNNGGGNACCTTGGNNGNTCGTTCNTCN
ANGGGNANGNCCGCAAANAANNCGAAGGCGGTAAAGGGGNCCCTCCAAAGTTTNCAGAGGAATCTGGNAAAAGNNAC
GGTGGCCNNGNGGNAAANCCNACNAAAGNAAGCCGGGNNAAGTTACCCCTTNAAGNCCNGGAANTNGNNACCCGCCT
CNTCCNATGNAANAAAANCGGGGGGAANTCCGNNGGNAAAAGGGANNGGAACCCNGCTCACCCGGGGGCCNAGNGGG
GGCGACCCCNTTTCANGNCCTNCTNCTTTGNGGGGANNCCCCCGNAAAATGGNNGGCTTTTNNTGNCCCCCCNAANG
GCGCNGAAAAAACACCNCGGCCTTNTGGCCCGCCTTTGNGTTNGNATCNNAAACCAANAAAGCCGNTGTGGTG 
 
Terminal Primer -  
NNNNNNNNNNNNNNNNNNNNNNNNNNNGGCNGTNTTAGCANCGCNGTAGACGAGTCATGTGCTGGCGTTCAAATTTC
GCAGCAGCGGTTTCCTTTANTAGACTCGAGTGCGGCCGCAAGCTTCTATACGGCCATCTCCATCTTGATCGCCGGGT
GTGGAACGTAGTCGATCACCTCCATGTCCGTCAACTCGTAGTCCTCGAGGTACTGCCGCTCCTCCTTGAAGATGAGG
GTCGGGAACGCGTGCGGGACTCGCTCGAGCTGCGCCTTGAGGGCATCAACGTGGTTGCGGTAGACGTGGGCGTCGCC
GAGGGTGTGCACAAGCTCACCAGGCCGCAGACCCGTCGCCTTGGCAATGAGGATGGTGAGCAGCGCGTAGGAGGCAA
TGTTGAAGGGGACGCCAAGACCCATGTCACACGAGCGCTGGTACAACATGCAGGATAGCTCGCTCGTGTCTGTGTTC
ACGTAGAACTGAGCAAGCAAGTGGCACGGCGGCAGCGCCATCTTTTGCAGCGCGCACGGGTTCCAGGCAGTGACTAG
GAGGCGGCGGTCGTTCGGGTTCGTCTTGATGGTCTCCACGATGAGCTTGATCTGGTCCACCCCTTCGCCGTCGTAGT
TCGCTTCAAACCCCTTGTAATCTGCCCCGAAGTGGCGCCACTGGAAGCCGTAGACAGGGCCGAGGTCCATCTCCTTA
TTCTCTGTCAAGCCGCGGCTGTCGAGAAACTCGCGCGAACCGTTGCCGTCCCAGATGTGAATGTCCTTGTCTGCCAG
CAGGNTGCGCACTCGTCTCCCCGCGCAGGAACCACAGNAGCTCCTCGCAACACGCCGNGCCAAGAAAANACGCTTCG
TCGTTCAGCAGCNGCNAGGCGGTTGTCGCGTAAGGGAGAAGCGCATCTTGGGGCGCCNAAAGAGGCTGATGGTGCCC
CACGCCCGGTGCGGTCCCTCCTTNCACGATNCCCGTCTTTCTTNATGCGGTTNAAANCAGCCTCAAGGGTAANTGCC
CGCTNCNNCNNGGGTTGCNCCGGCANCTTANCTTNCAGAATNTTCGAAAATNNAANGCCCCNCCNCCCTCCCTTTTT
TGGGGGGTNCCNTAAAAAAAAACCCNNNGTTCCCNCCCCCNNGTCCNCNTTTTTNCGGGNGGAAAANAGAAAANAAN
AGGGNGTAANNCTAGGTNCCNTNTNGAAANATNCNGGTNNCAGNAANCTTCCNNCNNTTTTNCNAATACCNGGNAAA
AACTGNCNTCCNCNNAAAANCTGNGNAAANCCNAAAAAAAAAACTNTTTTCNGNACTTNNATNCNACNTTCTTTNNA
NAAAANGAAANTNCTGGTANAAACCNTTTTAANAACNAANTTGNTGCTCTCTCACGTNNTTTTCNCCNNGTANGGAT
NANA 
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APPENDIX D 
EXAMPLE TRACE FILE FROM UIUC 
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APPENDIX E 
NUCLEOTIDE SEQUENCE ALIGNMENT 
DHFRTS        1 ATGTCCAGGGCAGCTGCGAGGTTTAAGATTCCGATGCCGGAGACGAAGGCAGACTTTGCT 
Pro           1 ATGTCCAGGGCAGCTGCGAGGTTTAAGATTCCGATGCCGGAGACGAAGGCAGACTTTGCT 
Mid-Pro       1 ------------------------------------------------------------ 
RCMid-Term    1 ------------------------------------------------------------ 
RC-Term       1 ------------------------------------------------------------ 
 
DHFRTS       61 TTCCCCTCCCTGCGCGCCTTCTCCATCGTCGTGGCCCTCGATATGCAGCACGGCATCGGC 
Pro          61 TTCCCCTCCCTGCGCGCCTTCTCCATCGTCGTGGCCCTCGATATGCAGCACGGCATCGGC 
Mid-Pro       1 ------------------------------------------------------------ 
RCMid-Term    1 ------------------------------------------------------------ 
RC-Term       1 ------------------------------------------------------------ 
 
DHFRTS      121 GACGGCGAGTCGATCCCGTGGCGGGTGCCGGAGGACATGACGTTTTTCAAGAACCAGACG 
Pro         121 GACGGCGAGTCGATCCCGTGGCGGGTGCCGGAGGACATGACGTTTTTCAAGAACCAGACG 
Mid-Pro       1 ------------------------------------------------------------ 
RCMid-Term    1 ------------------------------------------------------------ 
RC-Term       1 ------------------------------------------------------------ 
 
DHFRTS      181 ACGCTGCTGCGCAACAAGAAGCCGCCGACGGAGAAGAAGCGCAACGCCGTCGTGATGGGC 
Pro         181 ACGCTGCTGCGCAACAAGAAGCCGCCGACGGAGAAGAAGCGCAACGCCGTCGTGATGGGC 
Mid-Pro       1 ------------------------------------------------------------ 
RCMid-Term    1 ------------------------------------------------------------ 
RC-Term       1 ------------------------------------------------------------ 
 
DHFRTS      241 CGCAAGACTTGGGAGAGCGTCCCGGTAAAGTTCCGACCACTCAAGGGACGGCTGAACATC 
Pro         241 CGCAAGACTTGGGAGAGCGTCCCGGTAAAGTTCCGACCACTCAAGGGACGGCTGAACATC 
Mid-Pro       1 ------------------------------------------------------------ 
RCMid-Term    1 -----------------------------------------------CGGGCTGAACATC 
RC-Term       1 ------------------------------------------------------------ 
 
DHFRTS      301 GTGTTATCCTCGAAGGCCACCGTCGAGGAGCTTCTGGCGCCGCTGCCGGAGGGACAGCGC 
Pro         301 GTGTTATCCTCGAAGGCCACCGTCGAGGAGCTTCTGGCGCCGCTGCCGGAGGGACAGCGC 
Mid-Pro       1 ------------------------------------------------------------ 
RCMid-Term   14 GTGTTATCCTCGAAGGCCACCGTCGAGGAGCTTCTGGCGCCGCTGCCGGAGGGACAGCGC 
RC-Term       1 ------------------------------------------------------------ 
 
DHFRTS      361 GCGGCGGCGGCGCAGGATGTGGTGGTGGTGAACGGCGGTCTGGCCGAGG-CGCTCCGCCT 
Pro         361 GCGGCGGCGGCGCAGGATGTGGTGGTGGTGAACGGCGGTCTGGCCGAGG-CGCTCCGCCT 
Mid-Pro       1 -------------------TGGTGGTGGTGAACGGCGGTCTGGCCGAGGCTCCTCCACCT 
RCMid-Term   74 GCGGCGGCGGCGCAGGATGTGGTGGTGGTGAACGGCGGTCTGGCCGAGG-CGCTCCGCCT 
RC-Term       1 ------------------------------------------------------------ 
 
DHFRTS      420 CCTCGCACGCCCGCTGTACTGCAGCTCCATCGAGACAGCGTATTGCGTC-GGTGGTGCGC 
Pro         420 CCTCGCACGCCCGCTGTACTGCAGCTCCATCGAGACAGCGTATTGCGTC-GGTGGTGCGC 
Mid-Pro      46 CCTCGCACGCCCGCTGTACTGCAGCTCCATCGAGACAGCGTATTGCGTC-GGTGGTGCGC 
RCMid-Term  134 CCTCGCACGCCCGCTGTACTGCAGCTCCATCGAGACAGCGTATTGCGTC-GGTGGTGCGC 
RC-Term       1 ------------------------------------------------------------ 
 
DHFRTS      479 AGGTTTACGCGGACGCCATGCTGTCGCCGTGCATCGAGAAACTGCAGGAAGTGTACCTGA 
Pro         480 A----------------------------------------------------------- 
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Mid-Pro     105 AGGTTTACGCGGACGCCATGCTGTCGCCGTGCATCGAGAAACTGCAGGAAGTGTACCTGA 
RCMid-Term  193 AGGTTTACGCGGACGCCATGCTGTCGCCGTGCATCGAGAAACTGCAGGAAGTGTACCTGA 
RC-Term       1 ------------------------------------------------------------ 
 
DHFRTS      539 CCCGCATCTACGCGACGGCGCCTGCGTGTACGCGCTTCTTTCCGTTTCCGCCCGAGAACG 
Pro             ------------------------------------------------------------ 
Mid-Pro     165 CCCGCATCTACGCGACGGCGCCTGCATGTACGCGCTTCTTTCCGTTTCCGCCCGAGAACG 
RCMid-Term  253 CCCGCATCTACGCGACGGCGCCTGCGTGTACGCGCTTCTTTCCGTTTCCGCCCGAGAACG 
RC-Term       1 ------------------------------------------------------------ 
 
DHFRTS      599 CGGCCACGGCGTGGGACCTGGCGTCGTCTCAGGGACGCCGCAAGAGCGAGGCGGAGGGCC 
Pro             ------------------------------------------------------------ 
Mid-Pro     225 CGGCCACGGCGTGTGACCTGGCGTCGTCTCAGGGACGCCGCAAGAGCGAGGCGGAGGGCC 
RCMid-Term  313 CGGCCACGGCGTGGGACCTGGCGTCGTCTCAGGGACGCCGCAAGAGCGAGGCGGAGGGCC 
RC-Term       1 ------------------------------------------------------------ 
 
DHFRTS      659 TCGAGTTCGAGATCTGCAAGTACGTGCCGCGCAACCACGAGGAGCGGCAGTACCTTGAGC 
Pro           ------------------------------------------------------------ 
Mid-Pro     285 TCGAGTTCGAGATCTGCAAGTACGTGCCGCGCAACCACGAGGAGCGGCAGTACCTTGAGC 
RCMid-Term  373 TCGAGTTCGAGATCTGCAAGTACGTGCCGCGCAACCACGAGGAGCGGCAGTACCTTGAGC 
RC-Term       1 ------------------------------------------------------------ 
 
DHFRTS      719 TGATTGACCGCATCATGAAGACGGGGATCGTGAAGGAGGACCGCACCGGCGTGGGCACCA 
Pro             ------------------------------------------------------------ 
Mid-Pro     345 TGATTGACCGCATCATGAAGACGGGGATCGTGAAGGAGGACCGCACCGGCGTGGGCACCA 
RCMid-Term  433 TGATTGACCGCATCATGAAGACGGGGATCGTGAAGGAGGACCGCACCGGCGTGGGCACCA 
RC-Term       1 ------------------------------------------------------------ 
 
DHFRTS      779 TCAGCCTCTTCGGCGCCCAGATGCGCTTCTCCCTACGCGACAACCGCCTGCCGCTGCTGA 
Pro             ------------------------------------------------------------ 
Mid-Pro     405 TCAGCCTCTTCGGCGCCCAGATGCGCTTCTCCCTACGCGACAACCGCCTGCCGCTGCTGA 
RCMid-Term  493 TCAGCCTCTTCGGCGCCCAGATGCGCTTCTCCCTACGCGACAACCGCCTGCCGCTGCTGA 
RC-Term       1 ------------------------------------------------------------ 
 
DHFRTS      839 CGACGAAGCGTGTCTTCTGGCGCGGCGTGTGCGAGGAGCTGCTGTGGTTCCTGCGCGGG 
Pro             ------------------------------------------------------------ 
Mid-Pro     465 CGACCAAGCGTGTCTTCTGGCGCGGCGTGTGCGAGG----------------------- 
RCMid-Term  553 CGACGAAGCGTGTCTTCTGGCGCGGCGTGTGCGAGGAGCTGCTGTGGTTCCTGCGCGGG 
RC-Term       1 ------------------------------------AGCTGCTGTGGTTCCTGCGCGGG 
 
DHFRTS      898 GAGACGAGTGCGCAGCTGCTGGCAGACAAGGACATTCACATCTGGGACGGCAACGGTTC 
Pro             ------------------------------------------------------------ 
Mid-Pro         ------------------------------------------------------------ 
RCMid-Term  612 GAGACGAGTGCGCAGCTGCTGGCAGACAAGGACATTCACATGNTGGGANCGGGCA 
RC-Term      24 GAGACGAGTGCGCAGCTGCTGGCAGACAAGGACATTCACATCTGGGACGGCAACGGTTC 
 
DHFRTS      957 GCGCGAGTTTCTCGACAGCCGCGGCTTGACAGAGAATAAGGAGATGGACCTCGGCCCTGT 
Pro             ------------------------------------------------------------ 
Mid-Pro         ------------------------------------------------------------ 
RCMid-Term  672 ANCGGTTTCGTC------------------------------------------------ 
RC-Term      83 GCGCGAGTTTCTCGACAGCCGCGGCTTGACAGAGAATAAGGAGATGGACCTCGGCCCTGT 
 
DHFRTS     1017 CTACGGCTTCCAGTGGCGCCACTTCGGGGCAGATTACAAGGGGTTTGAAGCGAACTACGA 
Pro             ------------------------------------------------------------ 
Mid-Pro         ------------------------------------------------------------ 
RCMid-Term      ------------------------------------------------------------ 
RC-Term     143 CTACGGCTTCCAGTGGCGCCACTTCGGGGCAGATTACAAGGGGTTTGAAGCGAACTACGA 
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DHFRTS     1077 CGGCGAAGGGGTGGACCAGATCAAGCTCATCGTGGAGACCATCAAGACGAACCCGAACGA 
Pro             ------------------------------------------------------------ 
Mid-Pro         ------------------------------------------------------------ 
RCMid-Term      ------------------------------------------------------------ 
RC-Term     203 CGGCGAAGGGGTGGACCAGATCAAGCTCATCGTGGAGACCATCAAGACGAACCCGAACGA 
 
DHFRTS     1137 CCGCCGCCTCCTAGTCACTGCCTGGAACCCGTGCGCGCTGCAAAAGATGGCGCTGCCGCC 
Pro             ------------------------------------------------------------ 
Mid-Pro         ------------------------------------------------------------ 
RCMid-Term      ------------------------------------------------------------ 
RC-Term     263 CCGCCGCCTCCTAGTCACTGCCTGGAACCCGTGCGCGCTGCAAAAGATGGCGCTGCCGCC 
 
DHFRTS     1197 GTGCCACTTGCTTGCTCAGTTCTACGTGAACACAGACACGAGCGAGCTATCCTGCATGTT 
Pro             ------------------------------------------------------------ 
Mid-Pro         ------------------------------------------------------------ 
RCMid-Term      ------------------------------------------------------------ 
RC-Term     323 GTGCCACTTGCTTGCTCAGTTCTACGTGAACACAGACACGAGCGAGCTATCCTGCATGTT 
 
DHFRTS     1257 GTACCAGCGCTCGTGTGACATGGGTCTTGGCGTCCCCTTCAACATTGCCTCCTACGCGCT 
Pro             ------------------------------------------------------------ 
Mid-Pro         ------------------------------------------------------------ 
RCMid-Term      ------------------------------------------------------------ 
RC-Term     383 GTACCAGCGCTCGTGTGACATGGGTCTTGGCGTCCCCTTCAACATTGCCTCCTACGCGCT 
 
DHFRTS     1317 GCTCACCATCCTCATTGCCAAGGCGACGGGTCTGCGGCCTGGTGAGCTTGTGCACACCCT 
Pro             ------------------------------------------------------------ 
Mid-Pro         ------------------------------------------------------------ 
RCMid-Term      ------------------------------------------------------------ 
RC-Term     443 GCTCACCATCCTCATTGCCAAGGCGACGGGTCTGCGGCCTGGTGAGCTTGTGCACACCCT 
 
DHFRTS     1377 CGGCGACGCCCACGTCTACCGCAACCACGTTGATGCCCTCAAGGCGCAGCTCGAGCGAGT 
Pro             ------------------------------------------------------------ 
Mid-Pro         ------------------------------------------------------------ 
RCMid-Term      ------------------------------------------------------------ 
RC-Term     503 CGGCGACGCCCACGTCTACCGCAACCACGTTGATGCCCTCAAGGCGCAGCTCGAGCGAGT 
 
DHFRTS     1437 CCCGCACGCGTTCCCGACCCTCATCTTCAAGGAGGAGCGGCAGTACCTCGAGGACTACGA 
Pro             ------------------------------------------------------------ 
Mid-Pro         ------------------------------------------------------------ 
RCMid-Term      ------------------------------------------------------------ 
RC-Term     563 CCCGCACGCGTTCCCGACCCTCATCTTCAAGGAGGAGCGGCAGTACCTCGAGGACTACGA 
 
DHFRTS     1497 GTTGACGGACATGGAGGTGATCGACTACGTTCCACACCCGGCGATCAAGATGGAGATGGC 
Pro             ------------------------------------------------------------ 
Mid-Pro         ------------------------------------------------------------ 
RCMid-Term      ------------------------------------------------------------ 
RC-Term     623 GTTGACGGACATGGAGGTGATCGACTACGTTCCACACCCGGCGATCAAGATGGAGATGGC 
 
DHFRTS     1557 CGTATAG- 
Pro             -------- 
Mid-Pro         -------- 
RCMid-Term      -------- 
RC-Term     683 CGTATAG- 

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DHFRTS is the L. major gene from the gene data bank, Pro is the sequencing data from 
the promoter primer of the recombinant L. major gene, Mid-Pro is the second primer 
that was designed to capture the mid-region of the recombinant gene sequence, 
RCMid-Term is the reverse compliment of the sequence from the mid-region of the 
recombinant gene sequence, and RC-Term is the reverse compliment of the terminal 
region of the recombinant gene sequence.   
